The British Orthopaedic Oncology Management audit protocol

Abstract

Metastatic bone disease (MBD) is a frequently encountered condition in trauma and orthopaedic practice, and delayed or inappropriate management may lead to worse oncological outcomes, dysfunction and reoperation. Updated guidance from the British Orthopaedic Oncology Society (BOOS) and British Orthopaedic Association (BOA), in 2015, aimed to raise awareness of such risks and to set clear standards for the provision of care in MBD patients. However, it is unclear whether these recommendations have been routinely adopted into clinical practice. BOOS and BOA aim to revise and update this guidance, and British Orthopaedic Association Standard for Trauma (BOAST) guidelines relating to MBD management are due to be published. The aim of this collaborative audit is to evaluate and benchmark current practice in the management of MBD prior to the publication of these BOAST guidelines, providing a baseline comparison for further future re-audit.

Poor adherence to national guidance in the management of patients with metastatic bone disease

“…The October 2023 issue of The Bone & Joint Journal contained a report from the British Orthopaedic Oncology Management (BOOM) audit of non-spinal bone metastases, which compared adherence to these guidelines with current clinical practice. 10 All patients presenting with metastatic bone disease were included, and were assessed in relation to seven auditable standards concerning their diagnosis, investigation, and management.…”